Technology is changing the way that people with type 1 diabetes are monitoring and managing their blood glucose levels
Diabetes technologies have transformed management options in type 1 diabetes. The most notable innovations include the commercialisation of insulin pumps, advancements in glucose monitoring and the capacity for these technologies to interact. New technologies offer enhanced flexibility in insulin delivery and opportunities to improve glucose levels and enhance quality of life. Recognising these benefits, the uptake of advanced technologies in Australians with type 1 diabetes has increased. In 2018–2019, 41% of children and 26% of adults attending hospital diabetes clinics managed their type 1 diabetes with insulin pumps, and 55% of children and 13% of adults newly commenced continuous glucose monitoring (CGM).1 In this article, we provide a guide to current diabetes technologies available in Australia, describe their benefits and discuss important factors in assessing an individual’s suitability.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australasian Diabetes Data Network. Research: demographic and clinical characteristics of adult participants, https://www.addn.org.au/research (viewed May 2020).
- 2. Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care 2017; 40: 1631–1640.
- 3. Hirsch IB, Battelino T, Peters AL, et al. Role of continuous glucose monitoring in diabetes treatment. Arlington, VA: American Diabetes Association, 2018. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/final_ada-abbott_cgm_compendium_final.pdf (viewed May 2020).
- 4. Martin CT, Criego AB, Carlson AL, Bergenstal RM. Advanced technology in the management of diabetes: which comes first — continuous glucose monitor or insulin pump? Curr Diab Rep 2019; 19: 50.
- 5. Hoss U, Budiman ES. Factory‐calibrated continuous glucose sensors: the science behind the technology. Diabetes Technol Ther 2017; 19: S44–S50.
- 6. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019; 42: 1593–1603.
- 7. Twigg S, Cohen N, Wischer N, Andrikopoulos S. Consensus position statement on: utilising the Ambulatory Glucose Profile (AGP) combined with the Glucose Pattern Summary to support clinical decision making in diabetes care. Sydney: Australian Diabetes Scoiety, 2020, https://diabetessociety.com.au/documents/ADSAGPConsensusStatement29022020-FINAL_000.pdf (viewed May 2020).
- 8. Maiorino MI, Signoriello S, Maio A, et al. Effects of continuous glucose monitoring on metrics of glycemic control in diabetes: a systematic review with meta‐analysis of randomized controlled trials. Diab Care 2020; 43: 1146–1156.
- 9. National Diabetes Services Scheme. Continuous and flash glucose monitoring. https://www.ndss.com.au/living-with-diabetes/managing-diabetes/continuous-glucose-monitoring/ (viewed May 2020).
- 10. Pickup JC. Insulin‐pump therapy for type 1 diabetes mellitus. N Engl J Med 2012; 366: 1616–1624.
- 11. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold‐based insulin‐pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224–232.
- 12. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low‐glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at‐home randomized crossover study: results of the PROLOG trial. Diab Care 2018; 41: 2155–2161.
- 13. Brown SA, Kovatchev BP, Raghinaru D, et al. Six‐month randomized, multicenter trial of closed‐loop control in type 1 diabetes. N Engl J Med 2019; 381: 1707–1717.
- 14. Alcántara‐Aragón V. Improving patient self‐care using diabetes technologies. Ther Adv Endocrinol Metab 2019; 10: 1–11.
No relevant disclosures.